KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Payables (2016 - 2025)

Historic Payables for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $798.4 million.

  • Biomarin Pharmaceutical's Payables rose 1156.7% to $798.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $798.4 million, marking a year-over-year increase of 1156.7%. This contributed to the annual value of $607.0 million for FY2024, which is 1114.83% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Payables stood at $798.4 million for Q3 2025, which was up 1156.7% from $684.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Payables' 5-year high stood at $798.4 million during Q3 2025, with a 5-year trough of $399.2 million in Q1 2021.
  • Moreover, its 5-year median value for Payables was $593.5 million (2024), whereas its average is $571.1 million.
  • In the last 5 years, Biomarin Pharmaceutical's Payables crashed by 1216.29% in 2021 and then soared by 4029.22% in 2023.
  • Biomarin Pharmaceutical's Payables (Quarter) stood at $498.3 million in 2021, then rose by 14.99% to $573.0 million in 2022, then rose by 19.23% to $683.1 million in 2023, then dropped by 11.15% to $607.0 million in 2024, then soared by 31.54% to $798.4 million in 2025.
  • Its last three reported values are $798.4 million in Q3 2025, $684.2 million for Q2 2025, and $628.2 million during Q1 2025.